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Abstract
Background: In the diagnosis of early-stage lung cancer photosensitizer-enhanced fluorescence
bronchoscopy with inhaled 5-aminolevolinic acid (5-ALA) increases sensitivity when compared to
white-light bronchoscopy. This investigation was to evaluate the in vivo tissue pharmacokinetics of
inhaled 5-ALA within the bronchial mucosa in order to define the time optimum for its application
prior to bronchoscopy.
Methods: Patients with known or suspected bronchial carcinoma were randomized to receive 200
mg 5-ALA via inhalation 1, 2, 3, 4 or 6 hours before flexible fluorescence bronchoscopy was
performed. Macroscopically suspicious areas as well as areas with visually detected porphyrin
fluorescence and normal control sites were measured spectroscopically. Biopsies for
histopathology were obtained from suspicious areas as well as from adjacent normal areas.
Results: Fluorescence bronchoscopy performed in 19 patients reveals a sensitivity for malignant
and premalignant changes (moderate dysplasia) which is almost twice as high as that of white-light
bronchoscopy, whereas specificity is reduced. This is due to false-positive inflammatory lesions
which also frequently show increased porphyrin fluorescence. Malignant and premalignant
alterations produced fluorescence values that are up to 5 times higher than those of normal tissue.
According to the pharmacokinetics of porphyrin fluorescence measured by spectroscopy, the
optimum time range for 5-ALA application is 80–270 min prior to fluorescence bronchoscopy, with
an optimum at 160 min.
Conclusion:  According to our results we propose inhalation of 5-ALA 160 min prior to
fluorescence bronchoscopy, suggesting that this time difference provides the best tumor/normal
tissue fluorescence ratio.
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Background
The detection of premalignant and early-malignant endo-
bronchial alterations is growing increasingly important in
the diagnosis of lung cancer, since an acceptable progno-
sis is strictly confined to the early stage of the disease [1,2].
However, a simple bronchoscopic method to recognize
such alterations is still needed. The yield in localizing very
early tumor stages by means of conventional white-light
bronchoscopy (WL) alone is poor [3,4]. Therefore, two
methods which take advantage of tissue fluorescence have
been developed. Autofluorescence (AF) utilizes the differ-
ence in light absorption and the concentration of fluoro-
phores in normal and malignant tissues [5,6].
Pharmacologically induced fluorescence can be activated
by the inhalation of a photosensitizer. 5-Aminolevulinic
acid (5-ALA), a commonly used photosensitizer prodrug,
is suitable and safe for endobronchial application [7-9].
Its discriminating ability depends on the cellular uptake
of 5-ALA and its subsequent intracellular transformation
into protoporphyrin IX (PPIX), the actual fluorescent
agent which accumulates in malignant tissue [10,11]. The
resulting fluorescence can then be detected bronchoscop-
ically by excitation with violet light and objectified by
spectroscopy [12]. In-vitro experiments show tumor/nor-
mal tissue fluorescence ratios best between 110 and 160
min after exposure to 5-ALA [13]. This study was to evalu-
ate the in-vivo tissue pharmacokinetics of inhaled 5-ALA
within the bronchial mucosa, in order to define the opti-
mum time range for its application.
Methods
We recruited patients with known or suspected bronchial
carcinoma. To avoid potential drug toxicity, patients with
a significant impairment of hepatic or renal function were
excluded. The local ethics committee approved the proto-
col, and a written informed consent was obtained from all
patients. 200 mg of 5-ALA (Medac, Hamburg, Germany)
dissolved in 5 ml isotonic NaCl, was applied via inhala-
tion with a conventional jet nebulizer (PARI-BOY, Pari,
Starnberg, Germany) according to Baumgartner et al. [8].
The patients were randomized to receive 5-ALA 1, 2, 3, 4
or 6 hours before bronchoscopy which was performed
under local anesthesia with conventional fiberscopes
(11001BC, 11004BC, K. Storz, Tuttlingen, Germany). A
sensitive video-camera (Endocam SL-PDD, K. Storz, Tut-
tlingen, Germany) was connected to the ocular of the
bronchoscope and images were displayed on a monitor.
The fluorescence mode was used first to search the bron-
chial system for abnormalities. Macroscopically, porphy-
rin fluorescence is characterized by a reddish color and
can be well identified by visual inspection. For this pur-
pose, an excitation light with wavelengths of 380–440 nm
(D-Light, Storz, Tuttlingen, Germany) was applied.
Although there are other systems for fluorescence bron-
choscopy available (e.g. the LIFE system), the results of tri-
als employing either technology can be directly compared
[14].
Spectroscopic measurements were made on various tissue
sites, using a sensitive spectrometer (Optical Multichan-
nel Analyser OMA, SI, Penzberg, Germany) which was
coupled between bronchoscope and video-camera using a
quartz fiber connected to a beam splitter. Porphyrin fluo-
rescence is found at wavelengths greater 630 nm, with a
peak emission at 635 nm.
Within areas of positive PPIX-fluorescence the tip of the
bronchoscope was directed towards the center of the
lesion, and only the central spot was used for spectro-
scopic analysis. Spectral data were normalized for distance
by an application of scattered light at 840 nm, which is
reflected from the bronchial tissue. The quantity of por-
phyrin fluorescence can be calculated by the relation
between the intensity of autofluorescence, PPIX fluores-
cence, and diffuse backscatter at 520, 635 and 840 nm
according to the following equation:
[PPIX] ~ [I(635 nm)-0.65*I(520 nm)]/I(840 nm)
(1)
PPIX = porphyrin fluorescence [arbitrary units]
I = Intensity [spectroscopically measured value]
Spectroscopy was performed in all macroscopically suspi-
cious areas as well as in areas showing porphyrin fluores-
cence. Each measurement was repeated three times. In
addition, biopsies were obtained from these areas. As a
control, adjacent non-suspicious areas were also analyzed
spectroscopically and biopsied. The histological results of
the biopsies were categorized as "Normal", "Inflamma-
tion", "Metaplasia", "Dysplasia Grade I-III (mild, moder-
ate, severe)" or "Malignant". Up to "Mild Dysplasia" the
findings were classified as "Benign". All other findings
were classified as "(Pre)Malignant". The application-time
dependent spectral PPIX values according to equation 1
were fitted for the benign (≤ mild dysplasia) and the
(pre)malignant (≥ moderate dysplasia) histologic find-
ings separately. The fit function used was a normal distri-
bution applied to a logarithmic time scale. The two
histological ensembles were determined and further ana-
lyzed with the Mann-Whitney rank sum test.
Results
Nineteen patients were investigated. Basline characteris-
tics of all patients are displayed in table 1. As already dem-
onstrated by Baumgartner et al. [8] no side effects were
observed during and after 5-ALA inhalation. Based on the
spectroscopic measurements of critical findings (≥ moder-
ate dysplasia) versus normal findings, a method was
established to objectify visible color contrasts seen in neo-Respiratory Research 2007, 8:33 http://respiratory-research.com/content/8/1/33
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plastic lesions. Figure 1 shows an example for a squamous
cell carcinoma with an obvious colour change (red) for
the PPIX image. It is difficult to differentiate tumor mar-
gins in the white-light mode, even when the tumor
appears to be distinctive or exophytic, since there is no
detectable color contrast.
Figure 2 illustrates the mean spectral characteristics for
tumor and normal tissue after excitation with wavelengths
of 380–440 nm. Spectra have been normalized to the
remission peak at 840 nm. The spectral quantities of PPIX
fluorescence according to equation 1, the visual ratings
and the corresponding histological results of each biopsy
site are displayed in Table 2. Due to a low signal-to-noise
ratio, not all measurements were evaluable. Three patients
(Pat# 14+15+16) had to be excluded from analysis, since
no valid fluorescence values could be obtained. For this
reason, the projected number of patients was eventually
extended from 15 to 19.
When tumor tissue is compared to normal tissue, a
reduced autofluorescence, but a marked increase in PPIX
fluorescence becomes evident. Sensitivity, specificity, neg-
ative predictive values, and positive predictive values were
calculated from the visual ratings of the findings obtained
by white-light and fluorescence bronchoscopy in compar-
ison to histology (Figure 3). Fluorescence bronchoscopy
reveals a sensitivity which is nearly twice as high as in
white-light bronchoscopy. The specificity, however,
shows a significant lower level. This is explained by false-
positive findings during fluorescence bronchoscopy
which were due to the concomitance of inflammatory
lesions exhibiting fluorescence values between normal tis-
sue and lesions ≥ moderate dysplasia.
Eventually the calculated fluorescence values were plotted
against the time between 5-ALA application and bron-
choscopy (Figure 4). It is demonstrated that the different
histological classifications produce separate pharmacoki-
netics. When the curves were fitted to represent normal
distributions on a logarithmic time-scale, the maximum
fluorescence value for lesions ≥ moderate dysplasia is at
160 min after 5-ALA application. The maximum for nor-
mal tissue is at 200 min after 5-ALA application. The spec-
tral values of lesions ≥ moderate dysplasia and of normal
tissue differ significantly in the time range of 80 min to
270 min after 5-ALA inhalation (p < 0.01, Mann-Whitney
rank sum test). The same accounts for the difference
between lesions ≥ moderate dysplasia and lesions ≤ mild
dysplaisa. Between the spectra of normal tissue and
lesions ≤ mild dysplasia there is no siginificant difference.
The mentioned time range is a reasonable period for the
detection of 5-ALA-induced PPIX fluorescence, since
lesions  ≥ moderate dysplasia within this time window
exhibit fluorescence values that are 5 times higher (mean
value) than those of normal tissue. The PPIX fluorescence
values of lesions ≤ mild dysplasia (median 1,55 a.U.) lie
between the values of lesions ≥ moderate dysplasia
(median 3,4 a.U.) and the values of normal tissue
(median 1,3 a.U.).
Discussion
In contrast to white-light bronchoscopy, pharmacologi-
cally induced fluorescence offers certain advantages. The
present data provide evidence that the pharmacologically
active process of 5-ALA uptake and metabolism produces
a higher sensitivity than white-light bronchoscopy alone.
However, this advantage is partly compensated by a
reduced specificity, since e.g. some areas of inflammation
or metaplasia can generate false-positive results. In this
context the issue of "per lesion analysis" has to be taken
Table 1: Baseline characteristics of the evaluated patients (n = 16)
Age-yr
Mean 69.0
Range 58 – 86
Male sex no. (%) 10 (63)
Smoker or ex-smoker no. (%) 14 (88)
Obstructive lung disease no. (%) 5 (31)
Vital capacity (l)
Mean 2.72
Range 1.14 – 4.61
FEV1 (l)
Mean 1,85
Range 1.10 – 3.16
PaO2 (mmHg)
Mean 68.1
Range 58.4 – 75.7
PaCO2 (mmHg)
Mean 38.2
Range 33.0 – 43.4Respiratory Research 2007, 8:33 http://respiratory-research.com/content/8/1/33
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into consideration since it may represent a potential flaw
in the statistical evaluation concerning sensitivity, specifi-
city and predictive values, as impressively demonstrated
by Chang et al. [15]. As only two sites (one positive area
and one control) were biopsied in most of the study sub-
jects our results, however, represent more a "per subject
analysis" than a "per lesion analysis".
According to in-vitro studies with co-cultures, best fluores-
cence intensities were to be expected between 110 and
160 min after inhalation of 5-ALA [13]. Our results favor
the performance of fluorescence bronchoscopy within a
time period between 80 and 270 min after the inhalation
of 5-ALA, with a calculated maximum of fluorescence
intensity at 160 min. In order to seize the highest possible
discrimination between normal and pathologic tissue, we
therefore recommend the application of 5-ALA 160 min
before fluorescence bronchoscopy is performed.
The observed heterogeneity of 5-ALA-induced fluores-
cence intensity in premalignant and malignant changes
may be a distinctive feature of 5-ALA metabolism as well
as the patterns of tumor invasion. This was also found in
experiments with co-cultures, even after correction for
tumor cell density [16]. Correlations between the baseline
characteristics of the patients and fluorescence values were
not detected. Thus, it remains unclear, whether smoking
status or lung function excert influence on 5-ALA metabo-
lism. Despite this heterogeneity, the fluctuations in our
spectroscopic measurements are still small enough to
allow discrimination between harmless and severe find-
ings, with fluorescence values differing by a factor of five
(Figure 4). In this context, the adoption of a normal dis-
tribution on a logarithmic time-scale was superior to a
three compartment model. It delivers the time and the
intensity of the calculated peak fluorescence values with
discriminating differences between normal and patho-
logic findings. As reported in other studies [6,9,17], there
is always an increase in sensitivity and a decrease in spe-
cificity when, for the detection of (pre)malignant changes,
white-light bronchoscopy is combined with ALA-
enhanced fluorescence bronchoscopy.
Conclusion
5-ALA-supported fluorescence bronchoscopy enables an
increased sensitivity in the bronchoscopic detection of
endobronchial malignant and premalignant changes. The
clinical implication of this method is the possibility to
discover very early-stage lung cancer, in order to markedly
improve healing rates and prognosis. With 160 min we
propose an optimized time-point in the application of 5-
ALA prior to the performance of fluorescence bronchos-
copy. In this context, this study can contribute impor-
tantly to the efficiency of fluorescence bronchoscopy,
White-light image (A1) and 5-ALA-induced PPIX fluorescence image (A2) of a patient with squamous cell carcinoma Figure 1
White-light image (A1) and 5-ALA-induced PPIX fluorescence image (A2) of a patient with squamous cell carcinoma.
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Means and SEM of tumor tissue spectra and normal tissue spectra after inhalation of 200 mg of 5-ALA in the time range from  80–270 min prior to investigation Figure 2
Means and SEM of tumor tissue spectra and normal tissue spectra after inhalation of 200 mg of 5-ALA in the time range from 
80–270 min prior to investigation.
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Table 2: Fluorescence values and histological results of all biopsy sites
Pat # Time after 5-ALA 
inhalation [min]
Histological result and visual fluorescence Fluorescence "pathologic tissue" [a.u.] 
measurement 1–3
Fluorescence "normal tissue" [a.u.] 
Measurement 1–3
1 135 Sc + Sqc + 5.0 3.7 - 2.7 2.6 -
2 2 4 5 S q c  + 3 . 4 -----
3 75 Sqc + 1.0 - - 0.5 - -
4 85 Ade + Ade + No + 6.9 3.4 1.6 1.0 0.2 2.2
5 345 Inf + 1.4 - - 0.5 - -
6 225 Met + Hyp + 3.0 6.2 - 1.3 2.8 -
7 135 Hyp + Hyp - 5.2 2.6 - 1.4 1.1 -
8 60 Met + Sqc + 2.7 1.4 - 2.1 0.3 -
9 290 No + Inf + Inf + 1.2 3.2 1.7 - 1.6 -
10 195 Hyp + Sqc + 2.5 6.3 - 0.3 1.3 -
1 1 3 9 0 I n f  + A d e  + 1 . 2 1 . 1 ----
12 165 Inf + Met - Inf - 1.2 0.7 0.8 0.4 0.8 -
13 140 Hyp - Inf - Inf - 1.2 1.3 1.4 - - 0.9
1 4 1 9 5 H y p  + H y p  + ------
1 5 2 1 0 D y s  I I  + D y s  I I  + ------
1 6 1 8 0 S q c  + I n f ------
17 255 Sqc + Dys III + 3.3 3.2 - 2.2 2.2 -
18 180 TBC + 3.0 - - 0.2 - -
19 210 Sqc + Sqc + 5.0 3.7 - 2.1 2.8 -
Abbreviations: No = normal, Inf = inflammation, TBC = tuberculosis, Hyp = hyperplasia, Met = metaplasia, Dys = dysplasia grading I-III (mild, 
moderate, severe), Sqc = squamous carcinoma, Sc = small cell carcinoma, Ade = adenocarcinoma, + = fluorescence positive (visually), - = 
fluorescence negative (visually), a.u. = arbitrary units. Missing values represent measurements with low signal-to-noise ratio.Respiratory Research 2007, 8:33 http://respiratory-research.com/content/8/1/33
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particularly with regard to the in-vivo kinetics of 5-ALA.
Clinical trials, however, will have to evaluate the signifi-
cance and the clinical relevance of this method. Of partic-
ular interest will be the comparison with autofluorescence
bronchoscopy and, especially, whether the addition of
inhaled 5-ALA can further improve this technique, since a
large multicenter trial has recently shown a benefit for
autofluorescence bronchoscopy over white light bron-
choscopy [18].
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
HH carried out the bronchoscopic examinations, partici-
pated in spectroscopy and drafted the manuscript. JP car-
ried out all spectroscopic measurements, took part in
writing the manuscript and performed the statistical anal-
ysis. HS, RB, FG and RMH conceived of the study, and par-
ticipated in its design and coordination. All authors read
and approved the final manuscript.
Values of PPIX-fluorescence in normal findings, findings ≤ mild dysplasia and findings ≥ moderate dysplasia plotted against the  time between 5-ALA application and spectroscopy Figure 4
Values of PPIX-fluorescence in normal findings, findings ≤ mild dysplasia and findings ≥ moderate dysplasia 
plotted against the time between 5-ALA application and spectroscopy. Fitted curves are normal distributions on a 
logarithmic time scale. 19* patients/33 biopsies/86 spectra, * insufficient spectra in 3 patients. Arrows represent the SEM of the 
maxima of the adopted curves in time and value.
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Sensitivity and specificity of fluorescence bronchoscopy and  white-light bronchoscopy in relation to histology results Figure 3
Sensitivity and specificity of fluorescence bronchos-
copy and white-light bronchoscopy in relation to his-
tology results. n = 19 patients, 38 biopsies; Abbreviations: 
Sens = Sensitivity, Spec = Specificity, PPV = Positive predic-
tive value, NPV = Negative predictive value
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